Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: Taxol and vindesine

Biochemical Pharmacology

Volumn 66, Issue 5, 2003, Pages 739-748

  Merighi, Stefania ^a   Mirandola, Prisco ^a,b   Varani, Katia ^a   Gessi, Stefania ^a   Capitani, Silvano ^a   Leung, Edward ^c   Baraldi, Pier Giovanni ^a   Tabrizi, Mojgan Aghazadeh ^a   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c King Pharmaceuticals   (United States)

Author keywords

Adenosine; Keratinocytes; Melanoma; Pyrazolotriazolopyrimidine derivatives; Taxol; Vindesine

Indexed keywords

ABC TRANSPORTER; PACLITAXEL; PYRAZOLOTRIAZOLOPYRIMIDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VINDESINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIZATION; HUMAN; HUMAN CELL; KERATINOCYTE; MELANOMA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0041429153     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00400-3     Document Type: Article

References (33)

1. Bajetta E., Del Vecchio M., Bernard-Marty C. Metastatic melanoma: chemotherapy. Semin. Oncol. 29:2002;427-445.
2. Feun L.G., Savaraj N., Hurley J., Marini A., Lai S. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer. 88:2000;584-588.
3. Nathan F.E., Berd D., Sato T., Mastrangelo M.J. Paclitaxel and tamoxifen: an active regimen for patients with metastatic melanoma. Cancer. 88:2000;79-87.
4. Molinari A., Calcabrini A., Meschini S., Stringaro A., Del Bufalo D., Cianfriglia M., Arancia G. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int. J. Cancer. 75:1998;885-893.
5. Brown J.R., Cornell K., Cook P.W. Adenosine- and adenine-nucleotide-mediated inhibition of normal and transformed keratinocyte proliferation is dependent upon dipyridamole-sensitive adenosine transport. J. Invest. Dermatol. 115:2000;849-859.
6. 3 adenosine receptor. J. Cell Physiol. 186:2001;19-23.
7. Merighi S., Mirandola P., Milani D., Varani K., Gessi S., Klotz K.N., Leung E., Baraldi P.G., Borea P.A. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J. Invest. Dermatol. 119:2002;923-933.
8. 3 receptor subtype. Curr. Top. Med. Chem. 3:2003;463-469.
9. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:2001;527-552.
10. Blay J., White T.D., Hoskin D.W. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57:1997;2602-2605.
11. Barry C.P., Lind S.E. Adenosine-mediated killing of cultured epithelial cancer cells. Cancer Res. 60:2000;1887-1894.
12. 3 receptor agonists. Biochem. Biophys. Res. Commun. 219:1996;904-910.
13. 3 antagonists. Biochem. Biophys. Res. Commun. 232:1997;317-322.
14. 3 adenosine receptor affects cell cycle progression and cell growth. Naunyn Schmiedebergs Arch. Pharmacol. 361:2000;225-234.
15. 3 adenosine receptor activation and its suppression by isoproterenol. Exp. Cell Res. 257:2000;111-126.
16. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol. Pharmacol. 59:2001;76-82.
17. Schrier S.M., van Tilburg E.W., van der Meulen H., Ijzerman A.P., Mulder G.J., Nagelkerke J.F. Extracellular adenosine-induced apoptosis in mouse neuroblastoma cells: studies on involvement of adenosine receptors and adenosine uptake. Biochem. Pharmacol. 61:2001;417-425.
18. Fishman P., Bar-Yehuda S., Vagman L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res. 58:1998;3181-3187.
19. Fishman P., Madi L., Bar-Yehuda S., Barer F., Del Valle L., Khalili K. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene. 21:2002;4060-4064.
20. 3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp. Cell Res. 269:2001;230-236.
21. 3 adenosine receptors in Jurkat T cells. Br. J. Pharmacol. 134:2001;116-126.
22. Merighi S., Baraldi P.G., Gessi S., Iannotta V., Klotz K.N., Leung E., Mirandola P., Tabrizi M.A., Varani K., Borea P.A. Adenosine receptors and human melanoma. Drug Dev. Res. 58:2003;377-385.
23. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, Borea PA. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther, in press.
24. 3 adenosine receptors. Mol. Pharmacol. 57:2000;968-975.
25. 3 receptor antagonists. Trends Pharmacol. Sci. 21:2000;456-459.
26. Merighi S., Varani K., Gessi S., Cattabriga E., Iannotta V., Uluoglu C., Leung E., Borea P.A. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br. J. Pharmacol. 134:2001;1215-1226.
27. Wiese M., Pajeva I.K. Structure-activity relationships of multidrug resistance reversers. Curr. Med. Chem. 8:2001;685-713.
28. Bakos E., Evers R., Sinko E., Varadi A., Borst P., Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 57:2000;760-768.
29. Goldstein L.J., Galski H., Fojo A., Willingham M., Lai S.L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G.M. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81:1989;116-124.
30. Berger W., Elbling L., Minai-Pour M., Vetterlein M., Pirker R., Kokoschka E.M., Micksche M. Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. Int. J. Cancer. 59:1984;717-723.
31. Martin C., Berridge G., Higgins C.F., Mistry P., Charlton P., Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58:2000;624-632.
32. Zamora J.M., Pearce H.L., Beck W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:1988;454-462.
33. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:1990;155-199.